tiprankstipranks
Embecta Corporation (EMBC)
NASDAQ:EMBC
US Market
Want to see EMBC full AI Analyst Report?

Embecta Corporation (EMBC) Blogger Opinions & Sentiment

121 Followers

Blogger Sentiment

Bearish: 60.00%
Sector Average
Neutral
EMBC Blogger sentiment is based on 5 Blogger Opinions. The Blogger sentiment is more Bearish than other stocks in the Healthcare sector.

Blogger Article Distribution

ArticleDistribution
80% SeekingAlpha
20% GuruFocus
The distribution of articles among the main online Financial Blogging platforms.

Top Blogger Bearish Predictions

BlackRock, Inc. Reduces Stake in Embecta Corp by Over 50%
GuruFocus
Embecta Growth Stalls Despite Strong Fiscal 2025 Results (Rating Downgrade)
SeekingAlpha
Recent negative articles by top bloggers.

Top Blogger Bullish Predictions

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
SeekingAlpha
Embecta: Strategic Reprioritization Holds Promise And Valuations Are Favorable
SeekingAlpha
Recent positive articles by top bloggers.

Financial Blogger Predictions​​

Blogger Performance
Any
Any
Blogger Sentiment
Any
Any

FAQ

What do Seeking Alpha bloggers think of EMBC?
Seeking Alpha’s Paul Franke has a Bullish Sentiment.
    What do Motley Fool contributors think of EMBC?
    Currently there's no blogger sentiment for EMBC.
    What Is EMBC’s Blogger Sentiment?
    EMBC’s Blogger Sentiment is Neutral.
      What was the most recent blogger prediction for EMBC?
      The most recent blogger prediction for EMBC was made by Paul Franke, who was Bullish on the stock.
        How can I follow the stock ratings of top Top Financial Bloggers?
        Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Stocks with the Highest Top Blogger Ratings in the Healthcare sector
          CADLCandel Therapeutics
          MLTXMoonLake Immunotherapeutics
          DFTXDefinium Therapeutics
          TGTXTG Therapeutics
          PGENPrecigen